Evidence map›Paper›PMID 40584463›Full record

ArticleNutrition and metabolic insights2025

Sarcopenic Obesity in Adult Patients: Prevalence and Risk Factors.

Sana Khamassi, Fatma Boukhayatia, Haifa Abdesselem, Emna Bornaz, Kamilia Ounaissa, Houda Bouhajja, Awatef Kacem, Amel Gammoudi, Rahma Mahjoub, Emna Talbi and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nutrition and metabolic insights, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sana KhamassiDepartment of Nutritional Diseases D, National Institute of Nutrition and Food Technology, Tunis, Tunisia.ORCID https://orcid.org/0009-0000-3835-2560
Fatma BoukhayatiaDepartment of Nutritional Diseases D, National Institute of Nutrition and Food Technology, Tunis, Tunisia.
Haifa AbdesselemDepartment of Nutritional Diseases D, National Institute of Nutrition and Food Technology, Tunis, Tunisia.
Emna BornazDepartment of Nutritional Diseases D, National Institute of Nutrition and Food Technology, Tunis, Tunisia.
Kamilia OunaissaDepartment of Nutritional Diseases D, National Institute of Nutrition and Food Technology, Tunis, Tunisia.
Houda BouhajjaUR17SP01-Clinical Biology Laboratory, National Institute of Nutrition and Food Technology, Tunis, Tunisia.
Awatef KacemObesity Research Unit, National Institute of Nutrition and Food Technology, Tunis, Tunisia.
Amel GammoudiObesity Research Unit, National Institute of Nutrition and Food Technology, Tunis, Tunisia.
Rahma MahjoubUR17SP01-Clinical Biology Laboratory, National Institute of Nutrition and Food Technology, Tunis, Tunisia.
Emna TalbiUR17SP01-Clinical Biology Laboratory, National Institute of Nutrition and Food Technology, Tunis, Tunisia.
Henda JamoussiObesity Research Unit, National Institute of Nutrition and Food Technology, Tunis, Tunisia.
Chiraz AmroucheDepartment of Nutritional Diseases D, National Institute of Nutrition and Food Technology, Tunis, Tunisia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Sarcopenia now constitutes a serious issue that can affect the obese adult population. The aims of our study were to estimate the prevalence of sarcopenia in a group of obese patients, investigate the impact of sarcopenic obesity (SO) on patient health and quality of life, and identify its risk factors. Methods: We conducted a cross-sectional descriptive observational study of a group of obese adult patients. Physical activity was assessed with the Ricci and Gagnon questionnaire and quality of life was evaluated using the SF-12 and ORWELL-97 questionnaires. SO was defined in accordance with the EASO-ESPEN consensus statement. Results: We included 100 patients with a mean age of 44.42 ± 13.25 years. SO was diagnosed in 19% of the study population. The assessment of the impact of SO revealed that it was associated with osteoarthritis ( Conclusion: It is essential to incorporate the screening for sarcopenia into the therapeutic approach for obese adult patients due to its clinical consequences and impact on individuals' quality of life.

Indexed as

obesityquality of liferisk factorssarcopenia

Identifiers

PMID40584463
PMCPMC12206272

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.